Editas Medicine Q3 EPS Estimate Boosted by HC Wainwright

Editas Medicine, Inc. (NASDAQ:EDIT) – Stock analysts at HC Wainwright boosted their Q3 2026 earnings estimates for Editas Medicine in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.20) per share for the quarter, up from their prior estimate of ($0.33). The consensus estimate for Editas Medicine’s current full-year earnings is ($0.91) per share. HC Wainwright also issued estimates for Editas Medicine’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.66) EPS, Q1 2027 earnings at ($0.20) EPS, Q2 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.21) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($0.70) EPS.

Other research analysts have also issued reports about the stock. TD Cowen restated a “buy” rating on shares of Editas Medicine in a research report on Wednesday, May 27th. Wall Street Zen upgraded Editas Medicine from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Editas Medicine in a research note on Friday, July 17th. Finally, Chardan Capital boosted their target price on Editas Medicine from $3.50 to $4.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Editas Medicine presently has a consensus rating of “Moderate Buy” and an average price target of $5.40.

Editas Medicine Price Performance

NASDAQ EDIT opened at $2.95 on Monday. Editas Medicine has a 1 year low of $1.66 and a 1 year high of $4.54. The stock has a market capitalization of $288.83 million, a PE ratio of -3.93 and a beta of 2.14. The company’s 50 day simple moving average is $2.89 and its two-hundred day simple moving average is $2.66.

Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.12. The company had revenue of $11.89 million during the quarter, compared to analysts’ expectations of $2.85 million. Editas Medicine had a negative net margin of 157.32% and a negative return on equity of 196.63%.

Insider Activity at Editas Medicine

In other news, CEO Gilmore Neil O’neill sold 15,380 shares of the firm’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $2.70, for a total transaction of $41,526.00. Following the sale, the chief executive officer owned 248,313 shares in the company, valued at approximately $670,445.10. This trade represents a 5.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 21,503 shares of company stock valued at $57,910. 3.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. bought a new stake in Editas Medicine during the third quarter worth about $36,000. Pallas Capital Advisors LLC purchased a new position in shares of Editas Medicine during the 2nd quarter valued at about $38,000. Captrust Financial Advisors purchased a new position in shares of Editas Medicine during the 2nd quarter valued at about $26,000. Sei Investments Co. bought a new stake in Editas Medicine in the 3rd quarter worth approximately $46,000. Finally, Abel Hall LLC bought a new stake in Editas Medicine in the 1st quarter worth approximately $36,000. Institutional investors own 71.90% of the company’s stock.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.